The headline trial: Pooled meta-analyses
What the trial found:
- GLP-1 RA in PCOS produced significant improvements in body weight (3 to 8 kg over 24 weeks), insulin resistance (HOMA-IR) and circulating androgen levels.
- Smaller RCTs (Jensterle, Frossing) showed restoration of menstrual regularity in 50 to 70 percent of treated women with PCOS over 6 months.
- No GLP-1 RA is FDA-approved for PCOS itself; eligibility depends on the patient meeting the obesity or T2D pathway.
Full trial detail
Cena et al. systematic review (Reproductive Sciences, 2023); Jensterle et al. (Endocrine Connections, 2014); Frossing et al. (Diabetes Obesity and Metabolism, 2018)
Meta-analyses 2023; original RCTs 2014–2018
GLP-1 RA in PCOS produced significant improvements in body weight (3 to 8 kg over 24 weeks), insulin resistance (HOMA-IR) and circulating androgen levels. Smaller RCTs (Jensterle, Frossing) showed restoration of menstrual regularity in 50 to 70 percent of treated women with PCOS over 6 months. No GLP-1 RA is FDA-approved for PCOS itself; eligibility depends on the patient meeting the obesity or T2D pathway.
Trial enrollment criteria
- PCOS diagnosis by Rotterdam criteria (two of: oligo/anovulation, hyperandrogenism, polycystic ovaries on ultrasound)
- Insulin resistance documented (HOMA-IR > 2.5) or prediabetes (HbA1c 5.7 to 6.4) or T2D
- BMI greater than or equal to 27 with comorbidity, or BMI greater than or equal to 30
Does this trial apply to you?
PCOS alone does not qualify under any major payer's PA criteria, but the vast majority of PCOS patients meet obesity-with-comorbidity or T2D criteria. The PA letter should be filed under those indications with PCOS as supporting clinical context (insulin resistance, hyperandrogenism, fertility implications), not as the primary indication.
What to ask your prescriber
- Whether PCOS diagnosis is documented by Rotterdam criteria
- Recent HbA1c, fasting insulin, HOMA-IR, free testosterone
- Whether a reproductive endocrinologist consultation strengthens the PA
- Whether you are planning pregnancy in the next 12 months (GLP-1 must be stopped before conception)
Editorial notes
- Discontinue GLP-1 at least 2 months before attempted conception. Restoration of ovulation can be rapid; effective contraception during titration is essential if pregnancy is not desired.
- GLP-1 RA does not replace metformin in PCOS; many patients are on combination therapy.
- Insurance reviewers reject PA letters that file under E28.2 (PCOS) alone, file under E66 + E28.2 + R73.03.
Or see the best programs for PCOS, ranked and reviewed.
Clinical trials for Polycystic ovary syndrome (PCOS) with metabolic syndrome
Or browse the full GLP-1 clinical trials directory, filterable by condition, state and phase.
Take it to your prescriber: PA letter templates
Editable prior-authorization letter templates that cite the registration trial above. Pick the plan your prescriber will submit to, copy the template, fill in the patient-specific findings and have your clinician sign and submit.
PCOS
Commercial and Medicare Advantage plans
obesity + comorbidity
Commercial and Medicare Advantage plans
type 2 diabetes
Commercial and Medicare Advantage plans
Not seeing your plan? The full PA letter library covers 20 plans × 10 indications = 200 templates. The appeal letter library handles denials.
Drug profiles
Other GLP-1 conditions
Editorial provenance
Editorial review by John, Editor on 2026-05-23, against Pooled meta-analyses (Meta-analyses 2023; original RCTs 2014–2018). We do not yet have a credentialed medical reviewer on staff (actively recruiting). This page summarises public registration-trial data and FDA labeling. It is not clinician-authored medical advice.
Disclaimer
Educational summary of published registration trial data. Not medical advice. Not a substitute for evaluation by a treating clinician. Trial-level results do not guarantee individual outcomes. Discuss eligibility, contraindications, dose adjustments and drug interactions with your prescriber. We do not have a credentialed medical reviewer on staff yet (actively recruiting); the content below is editor-written from public registration-trial publications and FDA labeling, not clinician-authored medical advice.